Zymedi has begun first human trials of ZMA001, a novel monoclonal antibody for treating Pulmonary Arterial Hypertension.

Encoded Therapeutics Reveals Approval from US FDA for IND Application and Consent from Australian Health Authorities for ETX101, a Genetic Treatment Prospect for Dravet Syndrome.

Scholar Rock's Study Reveals SRK-439's Potential Influence on Muscle Mass and Metabolic Health in Weight Loss Efforts.

Orchard Therapeutics Reveals Enrollment of Initial Participant in Key Study of OTL-203 Targeting Hurler's Syndrome in MPS-I.

Rani Therapeutics Reports Encouraging Initial Outcomes from Phase 1 Trial of Oral RT-111, an Anti-IL-12/23 Antibody.

Johnson & Johnson has announced encouraging initial findings from a critical Phase 3 trial with nipocalimab for treating generalized myasthenia gravis, as well as from a Phase 2 investigation in Sjögren's Disease.

The Stage 2 trial for Technoderma's drug, TDM-105795, reveals positive outcomes for hair regeneration in individuals with pattern baldness.

Sangamo Therapeutics Reveals New Findings from Phase 1/2 STAAR Research for Fabry Disease Indicating Continuous Efficacy and Unique Safety Data.

Findings on CSL and Arcturus' sa-mRNA technology suggest extended immunity compared to standard mRNA COVID booster shots.

Incyte has declared the establishment of an asset acquisition deal with MorphoSys AG, granting Incyte unique worldwide privileges for the drug tafasitamab.

MorphoSys AG has officially declared that it has formed a strategic alliance through a Business Merger Contract with Novartis data42 AG and the principal entity, Novartis AG.

Henlius Confirms Phase 1 Pharmacokinetic Equivalence Trial of Denosumab HLX14 Achieves Positive Outcome.